0001213900-17-010951.txt : 20171025 0001213900-17-010951.hdr.sgml : 20171025 20171025163537 ACCESSION NUMBER: 0001213900-17-010951 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20171023 FILED AS OF DATE: 20171025 DATE AS OF CHANGE: 20171025 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Sank Leonard CENTRAL INDEX KEY: 0001416089 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-35813 FILM NUMBER: 171153381 MAIL ADDRESS: STREET 1: 3 BLAIR ROAD CITY: CAPE TOWN STATE: T3 ZIP: 8005 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: ORAMED PHARMACEUTICALS INC. CENTRAL INDEX KEY: 0001176309 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 980376008 STATE OF INCORPORATION: DE FISCAL YEAR END: 0831 BUSINESS ADDRESS: STREET 1: HI-TECH PARK 2/4 GIVAT-RAM STREET 2: PO BOX 39098 CITY: JERUSALEM STATE: L3 ZIP: 91390 BUSINESS PHONE: 011 972-2-566-0001 MAIL ADDRESS: STREET 1: HI-TECH PARK 2/4 GIVAT-RAM STREET 2: PO BOX 39098 CITY: JERUSALEM STATE: L3 ZIP: 91390 FORMER COMPANY: FORMER CONFORMED NAME: Integrated Security Technologies, Inc. DATE OF NAME CHANGE: 20040614 FORMER COMPANY: FORMER CONFORMED NAME: IGUANA VENTURES LTD DATE OF NAME CHANGE: 20020625 4 1 f4102317sank_oramedpharm.xml OWNERSHIP DOCUMENT X0306 4 2017-10-23 0 0001176309 ORAMED PHARMACEUTICALS INC. ORMP 0001416089 Sank Leonard 3 BLAIR ROAD CAPE TOWN T3 8005 SOUTH AFRICA 1 0 0 0 Common Stock 2017-10-23 4 M 0 5631 6.00 A 287789 D Common Stock 2017-10-23 4 M 0 6373 6.00 A 294162 D Common Stock 78125 I Via spouse Common Stock 138889 I Via trust Warrant (right to buy) 6.00 2017-10-23 4 M 0 5631 1.1796 D 2012-11-02 2017-11-02 Common Stock 5631 0 D Warrant (right to buy) 6.00 2017-10-23 4 M 0 6373 D 2013-02-07 2018-02-07 Common Stock 6373 0 D Mr. Sank disclaims beneficial ownership of these shares. These shares consist of shares of common stock owned by a company wholly owned by a trust of which Mr. Sank is a trustee. Mr. Sank disclaims beneficial ownership of these shares. The number of shares underlying such warrant and the applicable exercise price reflect a one-for-twelve reverse stock split effected by the issuer on January 22, 2013. The shares and warrants were purchased as "units" at a price per unit of $4.44 in connection with the Issuer's 2012 private placement. The consideration was allocated to the shares and warrants based on relative fair value. The value allocated to the warrants was estimated by using the Black Scholes option-pricing model. The shares of common stock and warrants were granted to Mr. Sank as a finder's fee in connection with a 2012 private placement of the Issuer. /s/ Leonard Sank 2017-10-25